<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308334</url>
  </required_header>
  <id_info>
    <org_study_id>2498</org_study_id>
    <nct_id>NCT00308334</nct_id>
  </id_info>
  <brief_title>Effect of Domperidone on the Nutrient Composition of Preterm Mother's Breast Milk</brief_title>
  <official_title>A Double Blind Placebo Controlled Trial Examining the Effect of Domperidone on the Composition of Breast Milk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IWK Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Nurses Foundation (CNF)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IWK Health Centre</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of domperidone (given to lactating&#xD;
      mothers of very preterm infants) on the macronutrient composition of human milk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Domperidone, a drug that enhances upper gastric motility, is an anti-dopaminergic medication&#xD;
      that also elevates prolactin levels. It has been shown to safely increase the milk supply of&#xD;
      lactating women. To date, researchers have analyzed the effects of domperidone on lactating&#xD;
      woman with respect to the quantity of their milk production, adverse effects, and drug levels&#xD;
      in the breast milk. However, the effect of domperidone on the macronutrient composition of&#xD;
      breast milk has not been studied and current guidelines for fortification of human milk for&#xD;
      premature infants do not distinguish between those women using or those not using&#xD;
      domperidone. The purpose of this study is to evaluate the effect of domperidone (given to&#xD;
      lactating mothers of very preterm infants) on the macronutrient composition of human milk.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The protein levels from breast milk will be compared, between the two groups (taking into consideration the expected rate of decline associated with increasing postpartum days).</measure>
    <time_frame>days 0, 4, 7, and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The fat, carbohydrate, lactose, energy, calcium, phosphorus and sodium content of breast milk will be compared between domperidone and placebo groups.</measure>
    <time_frame>days 0, 4, 7, and 14,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast milk volumes (if the infant breast feeds, volume will be estimated using pre and post feeding weights)</measure>
    <time_frame>Daily X 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prolactin level</measure>
    <time_frame>Day 0, 4 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infant weights</measure>
    <time_frame>daily X 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breastfeeding rates</measure>
    <time_frame>two weeks after treatment completion and at discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Low Breast Milk Supply</condition>
  <arm_group>
    <arm_group_label>Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Domperidone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placeob- Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>10 mg po TID X 14 days</description>
    <arm_group_label>Domperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo- Sugar pill</intervention_name>
    <description>placebo po TID x 14 days</description>
    <arm_group_label>placeob- Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  i. Mother of an infant born less than 31 weeks gestation&#xD;
&#xD;
          -  ii. Women mechanically expressing breast milk using a double collecting system&#xD;
&#xD;
          -  iii. Experiencing lactation failure indicated by at least one of the following: A&#xD;
             decreasing milk supply (by greater than 30 percent from peak volume based on maternal&#xD;
             account) An inability to provide adequate breast milk to meet the daily nutritional&#xD;
             intake of their infant&#xD;
&#xD;
          -  iv. Women who have had little or no improvement in milk production following&#xD;
             education/counseling with a lactation consultant/Neonatal Intensive Care nurse with&#xD;
             respect to non-pharmacological techniques.&#xD;
&#xD;
          -  v. Postpartum period equal to or greater than three weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  i. Participants receiving any medication known to alter the effect of domperidone&#xD;
             (e.g.cimetidine, ranitidine, famotidine, and nizatidine) or medication that interacts&#xD;
             with domperidone (e.g. haloperidol, lithium).&#xD;
&#xD;
          -  ii. Experiencing mastitis&#xD;
&#xD;
          -  iii. Having a chronic or debilitating illness.&#xD;
&#xD;
          -  iv. Previous breast surgery&#xD;
&#xD;
          -  v. Having a known lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marsha L Campbell-Yeo, MN NNP-BC PhDc</last_name>
    <role>Principal Investigator</role>
    <affiliation>IWK Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Campbell-Yeo ML, Allen AC, Joseph KS, Ledwidge JM, Allen VM, Dooley KC. Study protocol: a double blind placebo controlled trial examining the effect of domperidone on the composition of breast milk [NCT00308334]. BMC Pregnancy Childbirth. 2006 May 23;6:17.</citation>
    <PMID>16719919</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2006</study_first_posted>
  <last_update_submitted>June 10, 2009</last_update_submitted>
  <last_update_submitted_qc>June 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marsha Campbell-Yeo</name_title>
    <organization>IWK Health Centre</organization>
  </responsible_party>
  <keyword>Domperidone</keyword>
  <keyword>breast milk</keyword>
  <keyword>breast milk composition</keyword>
  <keyword>preterm infant</keyword>
  <keyword>neonate</keyword>
  <keyword>nutrition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

